New genes implicated in deadly heart defect

LA JOLLA, CALIF. – July 17, 2023 – By identifying genes in patients and testing their effects in fruit flies, researchers from Sanford Burnham Prebys have found new genes that contribute to hypoplastic left heart syndrome (HLHS), a rare, life-threatening heart disease that occurs in infants. The findings, published in the journal eLife, bring scientists one step closer to unraveling the biology of this complex disease.

“Every case of HLHS is unique because there are many different things that can go wrong during the early development of the heart,” says senior author Rolf Bodmer, Ph.D., director of the Center for Genetic Disorders and Aging Research at Sanford Burnham Prebys. “If we’re able to uncover what drives this disease biologically, it may be possible to one day prevent the disease or reduce complications for people living with it.”

In babies with HLHS, the left side of the heart (left ventricle) is underdeveloped and unable to pump oxygenated blood to the rest of the body. The Centers for Disease Control and Prevention estimates that each year about 1,025 babies in the United States are born with HLHS, and it accounts for about 2–4% of all congenital heart defects. Though rare, HLHS is extremely dangerous—it is nearly always fatal without multiple open-heart surgeries.

Genetics is thought to be a major driver of HLHS, but the specific genes involved have remained a mystery. To look for genes that contribute to HLHS, the researchers sequenced the genomes of 183 people with HLHS and their parents, including a family in which the parents were genetically related to each other. Focusing on this family helped the researchers narrow their search to a few key genes.

“We inherit two different variants of each gene, one from each parent,” says Georg Vogler, Ph.D., a research assistant professor at Sanford Burnham Prebys and co-senior author of the study. “If both parents pass down a gene variant that can cause problems, then the effect of that gene variant is accentuated in the child. Because of this effect, this family gave us a unique opportunity to look for new genes that drive HLHS that may not be as apparent in other families.”

To test whether the genes they identified could be contributing to HLHS, the researchers performed genetic experiments on fruit fly hearts that are built with genes similar to those found in human hearts. They found that blocking the activity of these genes in flies interfered with their heart’s ability to contract, leading to significant heart defects.

“While more research will be needed to explore precisely how these genes result in heart defects, one hypothesis is that because certain gene variants make it harder for the heart to contract, blood can’t flow as easily to the left side of the heart, thus compromising its proper formation,” says Bodmer. “This could lead to the types of abnormalities seen in HLHS.”

While the researchers identified genes that can contribute to HLHS, they caution that it is unlikely we will find a single gene implicated in the disease in all cases.

“HLHS is driven by many genetic and environmental factors, but the more we can shed light on these factors, the better chance we have of finding new ways to prevent and treat the disease,” says Bodmer. “For example, it may be possible that increasing the activity of one of these genes could be enough to strengthen the heart and reduce the risk of heart complications in survivors.”

###

Additional authors on the study include Katja Birker, Shuchao Ge, James Marchant, Maria Azzurra Missinato, Sreehari Kalvakuri, Karen Ocorr, Alexandre R. Colas, Georg Vogler, Sanford Burnham Prebys; Natalie J. Kirkland, Adam J. Engler, Sanford Consortium for Regenerative Medicine; Jeanne L. Theis, Zachary C. Fogarty, Timothy J. Nelson and Timothy M. Olson, Mayo Clinic; and Paul Grossfield, UCSD School of Medicine.

The study was supported by grants from the National Institutes of Health (R01 HL054732, R01 HL153645, R01HL148827, R01 HL149992, R01 AG071464), a grant from the Wanek Foundation at the Mayo Clinic, and fellowships from the American Heart Association (18PRE33969593, 20POST35180048).

The study’s DOI is 10.7554/eLife.83385.

About Sanford Burnham Prebys

Sanford Burnham Prebys is an independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 45 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children’s diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at SBPdiscovery.org or on Facebook facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.